<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03469960</url>
  </required_header>
  <id_info>
    <org_study_id>IFCT-1701</org_study_id>
    <secondary_id>2017-002540-33</secondary_id>
    <nct_id>NCT03469960</nct_id>
  </id_info>
  <brief_title>Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr</brief_title>
  <acronym>DICIPLE</acronym>
  <official_title>A Randomized Phase 3 Trial Comparing Continuation Nivolumab-Ipilimumab Doublet Immunotherapy Until Progression Versus Observation in Treatment-naive Patients With PDL1-positive Stage IV Non-Small Cell Lung Cancer (NSCLC) After Nivolumab-Ipilimumab Induction Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intergroupe Francophone de Cancerologie Thoracique</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intergroupe Francophone de Cancerologie Thoracique</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non Small Cell lung cancer (NSCLC) remains the first cause of death by cancer in the World.
      For the patients presenting a NSCLC stage IV, the median of survival is about 15 months
      today. The chemotherapy with platinum is the standard treatment for these patients but
      immunotherapy showed these efficacy in 1st line for patients PD-L1 positive. On the other
      hand, the duration of treatment by immunotherapy is not clear. Indeed, prolonged responses
      and long survivals have been described in patients having interrupted the treatment. In the
      melanoma, a treatment of 6 months of ipilimumab demonstrated its efficacy. The objective of
      the study is to demonstrate that a treatment of 6 months followed by an observation (stop and
      go) is not less effective than a treatment given until progression or toxicity. This strategy
      would allow to decrease the accumulated toxicities, to improve the quality of life of the
      patients and to decrease the costs.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS1)</measure>
    <time_frame>24 months after randomization of the last subject</time_frame>
    <description>Time between the date of randomization and the first date of documented progression, as determined by BICR (Blinded Independent Central Review), or death due to any cause, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS2)</measure>
    <time_frame>24 months after randomization of the last subject</time_frame>
    <description>Time between the start date of the second line and the second date of documented progression, as determined by BICR, or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>24 months after randomization of the last subject</time_frame>
    <description>Time until definitive deterioration (TUDD) from the randomization time in the experimental arm B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>6, 12 and 18 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological correlative exploratory studies (PD-L1)</measure>
    <time_frame>6 months</time_frame>
    <description>PD-L1-stained % of tumor cells will be associated to the rate of disease control patients at 6 months, PFS1, PFS2 and OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological correlative exploratory studies (PD-L1 H score)</measure>
    <time_frame>6 months</time_frame>
    <description>PD-L1 H-score will be associated to the rate of disease control patients at 6 months, PFS1, PFS2 and OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological correlative exploratory studies (CD3/CD8)</measure>
    <time_frame>6 months</time_frame>
    <description>CD3/CD8 tumor infiltration will be associated to the rate of disease control patients at 6 months, PFS1, PFS2 and OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological correlative exploratory studies (neutrophil)</measure>
    <time_frame>6 months</time_frame>
    <description>neutrophil tumor infiltration will be associated to the rate of disease control patients at 6 months, PFS1, PFS2 and OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological correlative exploratory studies (cytokines)</measure>
    <time_frame>6 months</time_frame>
    <description>plasma concentration of different cytokines at baseline or at the randomization point, will be associated to the rate of disease control patients at 6 months, PFS1, PFS2 and OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological correlative exploratory studies (chemokines)</measure>
    <time_frame>6 months</time_frame>
    <description>plasma concentration of different chemokines at baseline or at the randomization point, will be associated to the rate of disease control patients at 6 months, PFS1, PFS2 and OS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1360</enrollment>
  <condition>Non-Small Cell Lung Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Arm A : standard treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 months of treatment by nivolumab + ipilimumab then nivolumab + ipilimumab then in case of progression platinum-based doublet recommended</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B : experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 months of treatment by nivolumab + ipilimumab then observation the in case of progression nivolumab + ipilimumab then in case of progression platinum-based doublet recommended</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Ipilimumab 1 mg/kg every 6 weeks</description>
    <arm_group_label>Arm A : standard treatment</arm_group_label>
    <arm_group_label>Arm B : experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab 3 mg/kg every 2 weeks</description>
    <arm_group_label>Arm A : standard treatment</arm_group_label>
    <arm_group_label>Arm B : experimental arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed Written Informed Consent:

             Subjects must have signed and dated an IRB/IEC approved written informed consent form
             in accordance with regulatory and institutional guidelines. This must be obtained
             before the performance of any protocol related procedures that are not part of normal
             subject care.

             Subjects must be willing and able to comply with scheduled visits, treatment schedule,
             and laboratory testing.

          2. Histologically-proven NSCLC (squamous or non-squamous)

          3. Stage IV (M1, including M1a pleural involvement) disease (8th classification TNM, UICC
             2015)

          4. ECOG PS &lt; 1

          5. Weight loss&lt; 10% in previous 3 months

          6. No prior systemic anticancer therapy (including EGFR or ALK inhibitors) given as
             primary therapy for advanced or metastatic disease.

          7. Age≥ 18 years, &lt;75 years

          8. Life expectancy &gt; 3 months

          9. Measurable tumor disease by CT or MRI per RECIST 1.1 criteria

         10. Available tumor samples for centralized PD-L1 immunohistochemistry analysis

         11. PD-L1 tumor content ≥ 1% and &lt; 50% tumor cells as assessed locally by the investigator
             center

         12. Adequate biological functions:

             Creatinine Clearance ≥ 50 mL/min (Cockcroft or MDRD or CKD-epi); neutrophiles ≥
             1500/mm3 ; platelets ≥100 000/mm3 ; Hemoglobin ≥ 9g/dL ; hepatic enzymes &lt; 3x ULN,
             total bilirubin ≤ 1,5 x ULN except for patients with proved, Gilbert syndrome (≤ 5 x
             ULN) or patients with hepatic metastases (≤ 3,0 mg/dL)

         13. Women of childbearing potential (WOCBP) and sexually active should use an efficacious
             contraception method within the 28 days preceding the first dose and during the 6
             months following the last dose of treatment. Women must have a negative serum or urine
             pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24
             hours prior to the start of study drug.

             For Male subjects who are sexually active with WOCBP, an efficacious contraception
             method should be used during the treatment and during the 7 months following the last
             dose.

             Investigators shall counsel WOCBP and male subjects who are sexually active with WOCBP
             on the importance of pregnancy prevention and the implications of an unexpected
             pregnancy. Investigators shall advise WOCBP and male subjects who are sexually active
             with WOCBP on the use of highly effective methods of contraception. Highly effective
             methods of contraception have a failure rate of &lt; 1% when used consistently and
             correctly. At a minimum, subjects must agree to the use of two methods of
             contraception, with one method being highly effective and the other method being
             either highly effective or less effective.

         14. Patient inclusion validated by a multidisciplinary meeting.

        Exclusion Criteria:

          1. Small cell lung cancer or tumors with mixt histology including a SCLC component

          2. Known EGFR activating tumor mutation (deletion LREA in exon 19, L858R ou L861X
             mutations in exon 21, G719A/S mutation in exon 18) or HER exon 20 insertion (either
             tissue or plasma cfDNA mutation).

          3. Known ALK or ROS1 gene rearrangement as assessed by immunohistochemistry, FISH or NGS
             sequencing

          4. Previous or active cancer within the previous 5 years (except for treated carcinoma in
             situ of the cervix or basal cell skin cancer). Patients with a prostate adenocarcinoma
             history within the previous 5 years could be included in case of localized prostate
             cancer, with good prognostic factors according to d'Amico classification (≤ T2a and
             Score de Gleason ≤ 6 and PSA (ng/ml) ≤ 10), provided they were treated in a curative
             way (surgery or radiotherapy, without any chemotherapy)

          5. Superior vena cava (SVC) syndrome persisting after SVC stenting

          6. Thoracic radiotherapy needed at initiation of tumor treatment, except bone palliative
             radiotherapy on a painful or compressive metastasis, respecting 4 weeks delay between
             the end of radiotherapy and the beginning of induction immunotherapy treatment

          7. Symptomatic untreated brain metastasis (without previous whole brain radiotherapy or
             stereotactic ablative brain radiotherapy or without surgical resection). At least 4
             weeks delay between the end of radiotherapy and the beginning of induction
             immunotherapy treatment should be respected. Asymptomatic brain metastasis, not
             needing corticosteroids greater than 10 mg prednisone equivalent daily or mannitol
             infusions, with no evolution on brain MRI or CT-scan within the previous month are
             allowed.

          8. History of previous primary immunodeficiency, organ transplantation needing an
             immunosuppressive treatment, any immunosuppressive drug within 28 days before
             randomization date, or history of severe toxicity (grade 3/4) by immune mechanism
             linked to another immunotherapy treatment.

          9. Systemic treatment with corticosteroids with greater dose than 10 mg prednisone
             equivalent daily, within 14 days before initiation of the immunotherapy induction.
             Inhaled, nasal or topic corticosteroids are allowed.

         10. History of active autoimmune disease including rheumatoid polyarthritis, Lupus,
             Wegener disease. Patients with type I diabetes, or hypothyroidism, or immune cutaneous
             disease (vitiligo, psoriasis, alopecia) not needing any immunosuppressive systemic
             treatment, are allowed to be included.

         11. Active inflammatory intestinal disease (diverticulosis, Crohn disease, Hemorrhagic
             recto-colitis, coeliac disease) or any serious chronic intestinal disease with
             uncontrolled diarrhea

         12. Active uncontrolled infection including tuberculosis, known acute viral hepatitis B
             and C according to serological tests. Patients with serological sequelae of cured
             viral hepatitis are allowed to be included.

         13. HIV known infection

         14. Living attenuated vaccine received within the 30 previous days

         15. Previous treatment with anti-PD-1, anti-PD-L1 or Anti-CTLA4 antibody

         16. Previous treatment with chemotherapy

         17. General serious condition such as congestive uncontrolled cardiac failure,
             uncontrolled cardiac arrythmia, uncontrolled ischemic cardiac disease (unstable angina
             or history of myocardial infarction in the previous 6 months), history or stroke
             within the 6 previous months

         18. Pre-existing lung interstitial disease as assessed by the diagnosis CT-scan.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Operations Manager</last_name>
    <phone>0156811046</phone>
    <phone_ext>33</phone_ext>
    <email>contact@ifct.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Amiens - CHU</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claire POULET, Pr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Angers - CHU</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thierrry Urban, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Annecy - CH</name>
      <address>
        <city>Annecy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dorine TEMPLEMENT, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Avignon - CH</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gilles Pichancourt, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bordeaux - Polyclinique Nord</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sigolène GALLAND-GIRODET, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
    <investigator>
      <last_name>Sigolène GALLAND GIRODET, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boulogne - Ambroise Paré</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Etienne GIROUX-LEPRIEUR, MD</last_name>
    </contact>
    <investigator>
      <last_name>Etienne GIROUX-LEPRIEUR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Caen - CHU Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeannick MADELAINE, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cahors - CH</name>
      <address>
        <city>Cahors</city>
        <zip>46000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patricia Barré, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Pontoise</name>
      <address>
        <city>Cergy Pontoise</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cécile DURAND, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Chambery</name>
      <address>
        <city>Chambery</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne BARANZELLI, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Chauny</name>
      <address>
        <city>Chauny</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick DUMONT</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Cholet</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe MASSON</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clamart - Hôpital Percy</name>
      <address>
        <city>Clamart</city>
        <zip>92140</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier BYLICKI, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clermont Ferrand - CHU</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lise THIBONNIER, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Colmar - CH</name>
      <address>
        <city>Colmar</city>
        <zip>68000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lionel MOREAU, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dijon - CAC</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laure Favier, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne-Claire TOFFART</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>La Roche Sur Yon - CH</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie MARCQ, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier - Pneumologie</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier Molinier, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexis CORTOT, Pr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas EGENOD, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Lyon Sud - Pneumologie</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sébastien COURAUD</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne MADROSZYK, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marseille - Hôpital Européen</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacques LE TREUT, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mont de Marsan - CH</name>
      <address>
        <city>Mont de Marsan</city>
        <zip>40000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jérome Dauba, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mulhouse - CH</name>
      <address>
        <city>Mulhouse</city>
        <zip>68000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Didier DEBIEUVRE, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nantes - Centre René Gauducheau</name>
      <address>
        <city>Nantes</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandrine HIRET, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Josiane OTTO, MD</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nîmes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylvie VAN HULST, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orléans - CH</name>
      <address>
        <city>Orléans</city>
        <zip>45000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adrien DIXMIER, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP Hopital Tenon - Pneumologie</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacques Cadranel, Pr</last_name>
      <phone>+33.1.56.01.65.31</phone>
      <email>contact@ifct.fr</email>
    </contact>
    <investigator>
      <last_name>Jacques Cadranel, pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital Bichat</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gérard Zalcman, PhD</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GH Paris Saint-Joseph</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Pierre TREDANIEL</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis APHP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ludovic DOUCET, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paris - Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie BEAUCAIRE-DANEL, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rouen - CHU</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luc Thiberville, Pr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Quentin - CH</name>
      <address>
        <city>Saint Quentin</city>
        <zip>02100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charles Dayen, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre René Huguenin</name>
      <address>
        <city>Saint-Cloud</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie-Ange Massiani, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HIA Begin</name>
      <address>
        <city>Saint-Mandé</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carole HELISSEY, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICL Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre FOURNEL, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Suresnes - Hopital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylvie Friard, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toulon - CHI</name>
      <address>
        <city>Toulon</city>
        <zip>83000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clarisse Audigier-Valette, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julien MAZIERES, Pr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric PICHON, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Versailles - CH</name>
      <address>
        <city>Versailles</city>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cécile DUJON, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Villefranche - Pneumologie</name>
      <address>
        <city>Villefranche</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luc ODIER</last_name>
      <email>contact@ifct.fr</email>
    </contact>
    <investigator>
      <last_name>Luc ODIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2018</study_first_submitted>
  <study_first_submitted_qc>March 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2018</study_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IFCT</keyword>
  <keyword>DICIPLE</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

